Multiple researchers (35, 36) have found that nintedanib can inhibit the activities of PDGF, VEGF, and FGF, and suppress the TGF - β and Wnt/β - catenin pathways, thereby delaying or controlling the disease progression of pulmonary fibrosis and lung cancer. This evidence concerns the gene VEGFA and lung carcinoma.